+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Neonatal Administration of a Specific Neuropeptide Y Antiserum Alters the Vasopressin Response to Haemorrhage and the Hypothalamic Content of Noradrenaline in Rats

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          The possibility that neuropeptide Y (NPY) exerts organizational effects on central noradrenergic systems was investigated by treating newborn rats with subcutaneous injections of a specific NPY-antiserum. Three months later, neuroendocrine function was determined by measuring plasma vasopressin following haemorrhage, since this response is known to be regulated by ascending noradrenergic pathways. Basal mean arterial pressure, heart rate and plasma vasopressin were similar in both control (normal rabbit serum-treated) and NPY-antiserum-treated rats. Treatment with this antiserum resulted in an impaired vasopressin response to haemorrhage, although the haemodynamic changes observed after this hypovolaemic challenge were similar to control rats. NPY and noradrenaline content in the hypothalamus and brainstem were examined at the end of these experiments. NPY-like immunoreactivity was similar in both groups of animals. However, electrochemical detection of noradrenaline after HPLC revealed significantly higher levels in the hypothalamus, but not brainstem, of NPY-antiserum-treated rats. The presence of enduring changes in noradrenaline levels and neurohypophyseal function following neonatal treatment with NPY-antiserum suggests a role for NPY in postnatal organization of the rat hypothalamus.

          Related collections

          Author and article information

          S. Karger AG
          02 April 2008
          : 45
          : 6
          : 507-509
          aMedical Unit, Charing Cross and Westminster Medical School, London; bMRC Group, Department of Neuroendocrinology, AFRC Institute of Animal Physiology and Genetics Research, Cambridge, UK
          124782 Neuroendocrinology 1987;45:507–509
          © 1987 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 3
          Rapid Communication


          Comment on this article